Citadel Advisors’s Bluejay Diagnostics BJDX Stock Holding History

Citadel Advisors’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,449	Closed	-$27.9K	–	13002
2025 Q4	$27.9K	Buy	+10,449	New	+$68.6K	﹤0.01%	12250
2024 Q4	–	Sell	-261	Closed	-$6.63K	–	14513
2024 Q3	$6.63K	Buy	+261	New	+$18.7K	﹤0.01%	13409
2024 Q2	–	Sell	-12	Closed	-$15.9K	–	14271
2024 Q1	$15.9K	Sell	12 -2	-14%	-$2.76K	﹤0.01%	13161
2023 Q4	$26.8K	Buy	+14	New	+$75.9K	﹤0.01%	12362
2023 Q2	–	Hold	0	–	-$4.28K	–	14350
2023 Q1	–	Hold	0	–	–	–	13968
2022 Q4	–	Hold	0	–	–	–	14068
2022 Q3	–	Sell	-1	Closed	-$32K	–	12616
2022 Q2	$32K	Buy	+1	New	+$35.5K	﹤0.01%	12179

Other funds holding BJDX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LGM

L1 Global Manager Melbourne $149M AUM

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citadel Advisors's BJDX Position: Q1 2026 in Review

Citadel Advisors sold out of Bluejay Diagnostics (BJDX) in Q1 2026, closing a stake of 10,449 shares — an estimated $27.9K sold.

Citadel Advisors first reported a position in BJDX in Q2 2022 and held it in 5 quarters. The position peaked at $32K in Q2 2022. 6 funds tracked by Wall St. Rank hold BJDX as of Q1 2026.

Citadel Advisors reported no remaining Bluejay Diagnostics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 10,449 Bluejay Diagnostics shares in Q1 2026, an estimated $27.9K.
Citadel Advisors first reported a position in Bluejay Diagnostics in Q2 2022 and held it in 5 quarters.
Citadel Advisors's Bluejay Diagnostics position peaked at $32K in Q2 2022.
6 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.